Bonti Announces Dosing of the First Patient in the SHINE-1 Phase 2 Clinical Study Evaluating EB-001 for Scar Reduction
In making its decision, the judging panel, consisting of leaders in venture capital and biotechnology, considered, among other attributes, the strength of Immusoft’s intellectual property, its ability to disrupt the current standard-of-care, as well as its commercialization strategy and expected value creation for shareholders.
Latest Financing to Enable Continued Clinical Development of Lead Product EB-001 to Treat Musculoskeletal Pain
The funding is first part of the company’s ongoing Series B round.
Fauad Hasan, CEO and Co-founder, to Spotlight the Company in San Francisco.